Recordati制药公司的Urorec(silodosin)在欧洲获准用于治疗良性前列腺增生(benign prostatichyperplasia,BPH)。Urorec原先由Kissei制药公司开发,此后Recordati公司获得其在45个欧洲国家的销售权,计划于2010年底或2011年初上市。另外,Almirall公司于2009年获得了该药在西班牙的 Recordore’s Urorec (silodosin) is approved for the treatment of benign prostatichyperplasia (BPH) in Europe. Urorec was originally developed by Kissei Pharmaceuticals and since then Recordati has acquired marketing rights in 45 European countries and plans to list it by the end of 2010 or early 2011. In addition, Almirall acquired the drug in Spain in 2009